Premium
New cyclooxygenase‐2 inhibitors for treatment of experimental autoimmune neuritis
Author(s) -
Miyamoto Katsuichi,
Oka Nobuyuki,
Kawasaki Teruaki,
Miyake Sachiko,
Yamamura Takashi,
Akiguchi Ichiro
Publication year - 2002
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.10019
Subject(s) - medicine , celecoxib , meloxicam , neuritis , cyclooxygenase , chronic inflammatory demyelinating polyneuropathy , polyneuropathy , gastroenterology , pharmacology , immunology , surgery , enzyme , antibody , biochemistry , chemistry
Abstract We analyzed two new cyclooxygenase‐2 (COX‐2) inhibitors, celecoxib (SC‐58635) and meloxicam, for the treatment of experimental autoimmune neuritis (EAN) in rats. Celecoxib and meloxicam significantly reduced clinical EAN score and histopathological damage of the sciatic nerve. They induced no serious side effects, whereas indomethacin used as a control caused severe intestinal ulceration and dysfunction of liver and kidney. These findings suggest that the new COX‐2 inhibitors may be useful as additional therapeutic agents for patients with Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy. © 2002 John Wiley & Sons, Inc. Muscle Nerve 25: 280–282, 2002 DOI 10.1002/mus.10019